Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Amarin Corporation plcNASDAQ: AMRN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 20.8M shares rose 0.8% year over year, in line with the +1.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.8% toward the trailing-twelve-month pace of +1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
20.8M+0.0% QoQ
Last fiscal yearDec 2025
20.75M+1.0% YoY
LTMMar 2026
20.78M+1.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.8%——
1 year+1.0%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
20.75M USD
Year-over-year change
+1.0%
4-year CAGR
+1.2%

Weighted Avg Shares vs competitors

How AMRN compares with its peers on the latest reported figures

  • AMRN's LTM Mar 2026 weighted avg shares of 20.78M shares is the 9th highest of the 11 companies compared; the peer median is 69.01M shares.
  • Its year-over-year change of +1.0% is the 8th highest of 10, against a peer median of +10.2%.
  • Over three fiscal years its annual growth of +1.1% compares with a peer median of +26.7%.
AMRN Competitors Peer median
Weighted Avg Shares for AMRN and competitors
Company Period LTM YoY 3-year CAGR
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
DBVTDBV Technologies S.A.LTM Mar 202688.66M -7.8%+3.7%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
ENGNenGene Holdings Inc.LTM Apr 202659.85M +25.2%+47.9%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
KRROKorro Bio, Inc.LTM Mar 20269.94M +8.7%+232.8%
Peer median (excluding AMRN) 69.01M+10.2%+26.7%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue583.19M369.19M306.91M228.61M213.65M
Cost of Revenue121.33M126.71M141.37M147.23M92.78M
Gross Profit461.86M242.48M165.54M81.38M120.87M
Gross Margin79.2%65.7%53.9%35.6%56.6%
Research & Development29.31M30.41M22.22M20.87M19.81M
Selling, General & Admin408.33M304.42M199.94M152.31M115M
Operating Expenses451.36M348.35M222.16M173.18M134.81M
Depreciation & Amortization2.86M3.1M2.97M3.01M3.03M
EBITDA14.28M(100.69M)(50.7M)(74.18M)(33.01M)
EBITDA Margin2.4%-27.3%-16.5%-32.4%-15.5%
Operating Income10.5M(105.87M)(56.62M)(91.8M)(13.94M)
Operating Margin1.8%-28.7%-18.4%-40.2%-6.5%
Interest Income1.22M2.82M11.86M13.4M10.85M
Interest Expense129K15K8K7K7K
Other Income / Expenses789K2.06M2.95M14.6M(22.11M)
Income Before Tax11.29M(103.81M)(53.67M)(77.2M)(36.05M)
Pre-Tax Margin1.9%-28.1%-17.5%-33.8%-16.9%
Income Tax Expense3.56M2M5.44M4.98M2.75M
Net Income7.73M(105.8M)(59.11M)(82.18M)(38.8M)
Net Margin1.3%-28.7%-19.3%-35.9%-18.2%
EPS (Basic)0.39(5.20)(3.00)(4.00)(1.80)
EPS (Diluted)0.38(5.20)(3.00)(4.00)(1.80)
Weighted Avg Shares19.8M20.06M19.7M20.55M20.75M
Weighted Avg Shares (Diluted)20.12M20.06M20.38M20.55M20.75M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.